Asia Pacific Cell and Gene Therapy CDMO Market Size, Share By Service Area (Cell Therapy, Plasmid DNA, Viral Vector, and Others), By Indication (Cancer, Cardiovascular Disease, Infectious Disease, Genetic Disorders, Neurological Disorders), By Phase (Phas

Cell and Gene Therapy CDMO Market Size, Share, By Product Type [Gene Therapy (Ex-Vivo, and In-Vivo), and Cell Therapy (CAR T-Cell Therapy, CAR-NK Cell Therapy, TCR-T Cell Therapy, and Others)], Services (Contract Development, and Contract Manufacturing), Phase (Pre-Clinical and Clinical), Application (Oncology, Immunology, Neurology, Cardiovascular, and Others), End User (Biopharmaceutical Companies, Academic Institutions, Hospitals, and Others), and Region - Trends, Analysis and Forecast till 2035

The Cell and Gene Therapy CDMO Market Report offers an in-depth exploration of emerging market trends, driving factors, challenges, and key segments that shape the industry. It includes a thorough examination of regulatory frameworks, company profiles, and the latest industry developments. The report delves into product development, positioning strategies, and the impact of new technologies on the market landscape. By identifying challenges and opportunities, the report provides a detailed roadmap for market growth.

Cell and gene therapy CDMOs are a growing market due to the increasing demand for innovative therapies, outsourced services, clinical trials, rare diseases, research, and investments. The increasing prevalence of chronic diseases and improving healthcare infrastructures in emerging countries create new opportunities. Innovations in manufacturing techniques, data analytics, artificial intelligence, and advanced gene editing technologies drive growth in the cell and gene therapy CDMO market.

• Cell and Gene Therapy CDMO Market size is valuated at USD 7.9 Billion in 2025.
• Target Market size is estimated to grow at a rate of USD 75.0 Billion by 2035 and at a registered CAGR of 28.0%.
• By product type, the cell therapy sector is attributed to rule over the cell and gene therapy CDMO market share.
• Appertaining from services, the contract manufacturing segment is expected to govern the cell and gene therapy CDMO market.
• On the basis of phase, the pre-clinical phase is anticipated to influence the target market.
• Stemming from application, the oncology segment is holding the superior position in the cell and gene therapy CDMO market.
• Based on end user, the biopharmaceutical companies is the end user which is dominating the cell and gene therapy CDMO market.
• Under region North America is the region which is attributed to lead the cell and gene therapy CDMO market share.
• Europe is the region which has the cell and gene therapy CDMO market, growing with the highest CAGR, during the forecast period.

Key Highlights:

• In April 2025, AGC Biologics had unveiled a new Cell and Gene Technologies Division, hubbed at the CDMO’s Milan Cell and Gene Center of Excellence. The Milan site offered 30 years of experience in cell and gene therapy, with nine commercial approvals and hundreds of GMP batches produced successfully. The site was tasked with the commercial manufacturing of the lentiviral vectors for Autolus Therapeutics' Aucatzyl and the lentiviral vector and genetically modified cell drug product for Orchard Therapeutics’ Lenmeldy.

Report Analysis:

Future Role of CDMOs in Cell Therapy:

• Automated, closed systems: Greater automation and use of closed-system manufacturing to transition away from manual equipment and single unit operations, overall reducing labor costs and training required for on-site personnel.
• Novel non-viral gene delivery and gene-editing technology: Use of non-viral technology (e.g., electroporation and lipid nanoparticles) and gene-editing tools (e.g., CRISPR) to push beyond viral-based cell therapy methods, broaden the toolbox of cell engineering approaches and enable multiple, precise edits for next-generation cell therapies.
• AI/machine learning (ML) process optimization: AI/ML approaches for process optimization and workflow standardization incorporating multimodal datasets.
• Allogeneic cell therapy development: Allogeneic cell therapy programs to replace the fit for-purpose tools that were developed for the autologous space and expand use in broader treatment settings and larger addressable populations.

Segmentation:

By Product Type:

• Gene Therapy

o Ex-vivo

In-vivo

• Cell Therapy

o CAR T-cell Therapy

CAR-NK Cell Therapy

TCR-T Cell Therapy

Others

By Services:

• Contract Development
• Contract Manufacturing

By Phase:

• Pre-Clinical
• Clinical

By Application:

• Oncology
• Immunology
• Neurology
• Cardiovascular
• Others

By End User:

• Biopharmaceutical Companies
• Academic Institutions
• Hospitals
• Others

By Region:

• North America

o U.S.

Canada

• Europe

o Germany

U.K.

France

Russia

Italy

Spain

Netherlands

Rest of Europe

• Asia Pacific

o China

India

Japan

Australia

Indonesia

Malaysia

South Korea

Rest of Asia Pacific

• Latin America

o Brazil

Mexico

Argentina

Rest of Latin America

• Middle East & Africa

o GCC

Israel

South Africa

Rest of the Middle East & Africa

The report also includes a competitive analysis with a detailed SWOT review, examining the strengths, weaknesses, opportunities, and threats of each leading company, as well as their market share and product offerings.

Cell and Gene Therapy CDMO Market Companies:

FUJIFILM Diosynth Biotechnologies

WuXi AppTec

Lonza

Thermo Fisher Scientific Inc.

Charles River Laboratories

Novartis AG

AGC Biologics

OmniaBio

Catalent, Inc

Evotec

Cytiva

Rentschler Biopharma SE

SK pharmteco Inc.

What Our Report Delivers:

• Regional & Country-Level Market Insights: Detailed market share analysis across key regions and countries to help you understand competitive positioning.
• Guidance for New Market Players: Actionable strategic recommendations for businesses entering the market, ensuring a strong foothold from the start.
• Comprehensive Market Forecasts: Reliable data projections for 2024, 2025, 2026, 2028, and 2032 to support long-term planning and investment decisions.
• In-Depth Market Dynamics: Analysis of drivers, restraints, opportunities, and emerging threats, along with challenges and high-potential investment areas.
• Data-Driven Business Strategies: Expert recommendations tailored to key market segments, backed by precise market evaluations.
• Competitive Intelligence: Mapping of prevailing industry trends and competitor strategies to identify growth opportunities.
• Detailed Company Profiles: In-depth analysis of major players, including their business strategies, financial performance, and recent developments.
• Supply Chain Innovations: Insights into the latest technological advancements and trends shaping supply chain efficiency.

FAQs:

Key Questions Answered in the Report.

1. What was the Cell and Gene Therapy CDMO Market size in 2025?

2. What is projected growth rate of the Cell and Gene Therapy CDMO Market during 2025-2035?

3. What are the key factors driving the Cell and Gene Therapy CDMO Market growth?

4. What are leading players in the Cell and Gene Therapy CDMO Market ?

5. What are the key regions analyzed in the Cell and Gene Therapy CDMO Market ?

6. Which region is dominating in the Cell and Gene Therapy CDMO Market ?
Show more